Operating cash flow was -$22.3M and free cash flow -$23.0M in 2026Q2 (-4.1% margin), with only one positive free cash flow quarter (2023Q4, $4.8M) across the window, indicating a sustained burn that depends on external funding and milestone receipts.
Nanobiotix S.A. (NBTX) cash flow statement — 15-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Cash from Operations | -69.46M | -33.42M | -19.55M | -12.48M | -37.1M | -29.87M | -27.54M | -41.17M | -25.98M | -20.95M | -18.28M | -16.82M | -8.56M | -6.83M | -3.76M | -4.87M |
| Operating CF Margin % | - | -112.75% | 271.92% | -34.46% | -776.86% | -1128.52% | -1184.43% | -1620.19% | -746.91% | -562.84% | -337.24% | -418.92% | -309.11% | -428.12% | -386.99% | -358.24% |
| Operating CF Growth % | -629.1% | -70.95% | -56.71% | 66.37% | -24.21% | -8.48% | 33.11% | -58.43% | -24.04% | -14.58% | -8.7% | -96.39% | -25.39% | -81.85% | 22.92% | - |
| Net Income | -104.97M | -23.96M | -68.13M | -39.7M | -57.04M | -47M | -33.59M | -50.91M | -30.34M | -26.14M | -21.88M | -17M | -9.56M | -8.14M | -5.33M | -5.25M |
| Depreciation & Amortization | 3.24M | 1.5M | 1.62M | 1.51M | 1.5M | 1.56M | 1.75M | 1.77M | 619K | 489K | 482.79K | 456.08K | 307.56K | 233.93K | 146.53K | 197.62K |
| Stock-Based Compensation | 5.9M | 3.54M | 4.3M | 3.3M | 3.17M | 3.2M | 2.92M | 4.32M | 1.87M | 2.6M | 1.99M | 1.29M | 252.26K | 597.96K | 451.2K | 266.26K |
| Deferred Taxes | 3K | 3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 31.58M | -11.1M | 42.53M | 22.78M | 15.87M | 17.07M | -5.38M | 7.24M | 1.43M | 1.19M | 713.52K | 1.36M | 941.57K | 1.05M | 1.43M | -4.24K |
| Working Capital Changes | -5.21M | -3.4M | 131K | -367K | -606K | -4.7M | 6.76M | -3.58M | 445K | 908K | 409.58K | -2.92M | -509.68K | -569.08K | 0 | -86.3K |
| Change in Receivables | -534.6K | 1.85M | -2.07M | -806K | -101K | 62K | -51K | -85K | 144K | -164K | 74.82K | -78.39K | -743 | 449 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -363.83K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -1.61M | -578K | -955K | -349K | 138K | -242K | -112K | -1.46M | 71K | -1.56M | -444.99K | -2.21M | -1.14M | -192.31K | -49.51K | 4.95M |
| Capital Expenditures | -1.53M | -538K | -846K | -328K | -92K | -228K | -96K | -1.09M | -416K | -1.34M | -400.1K | -1.49M | -963.26K | -196.32K | -45.39K | 0 |
| CapEx % of Revenue | - | 1.81% | -11.77% | 0.91% | 1.93% | 8.61% | 4.13% | 42.94% | 11.96% | 35.98% | 7.38% | 37.23% | 34.76% | 12.31% | 4.68% | - |
| Acquisitions | 53.71K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -136.99K | -40K | -109K | -21K | 230K | -14K | -16K | -368K | 487K | -224K | -44.88K | -710.88K | -179.16K | 4.01K | -4.12K | 0 |
| Cash from Financing | 116.37M | 37.42M | -5.13M | 46.77M | -5.65M | -5.18M | 111.77M | 41.49M | 14.85M | 48.55M | 22.9M | 3.06M | 37.71M | -358.13K | 15.27M | 177.37K |
| Debt Issued (Net) | 36.62M | 38.19M | -4.16M | -3.62M | -4.74M | -3.74M | 9.17M | 12.43M | 15.07M | -1.03M | 1.22M | 2.29M | 1.19M | -365K | 0 | 151.15K |
| Equity Issued (Net) | 85.14M | 1.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.39K | 0 | -1.89M | 0 | 14.7K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.39K | 0 | -1.89M | -1.11M | 0 |
| Other Financing | -5.4M | -2.31M | -980K | 50.39M | -916K | -1.44M | 102.6M | 29.06M | -223K | 49.58M | 21.67M | 771.79K | 36.52M | 1.89M | 15.27M | 11.53K |
| Net Change in Cash | 42.74M | 3.01M | -25.55M | 33.9M | -42.53M | -35.23M | 84.06M | -1.11M | -11.01M | 26.15M | 4.05M | -15.98M | 32.99M | 4.98M | 12.36M | 249.66K |
| Free Cash Flow | -71M | -33.97M | -20.4M | -12.8M | -37.2M | -30.1M | -27.63M | -42.26M | -26.4M | -22.29M | -18.68M | -18.32M | -9.53M | -7.03M | -3.8M | -4.87M |
| FCF Margin % | - | -114.59% | 283.69% | -35.36% | -778.79% | -1137.14% | -1188.56% | -1663.12% | -758.87% | -598.82% | -344.62% | -456.15% | -343.88% | -440.43% | -391.66% | -358.24% |
| FCF Growth % | - | -66.53% | -59.3% | 65.58% | -23.57% | -8.92% | 34.61% | -60.07% | -18.45% | -19.29% | -2.01% | -92.22% | -35.59% | -84.84% | 21.99% | - |
| FCF per Share | -1.45 | -0.71 | -0.43 | -0.35 | -1.07 | -0.87 | -1.13 | -1.95 | -1.34 | -1.27 | -1.22 | -1.30 | -0.74 | -0.65 | -0.46 | -3.17 |
| FCF Conversion (FCF/Net Income) | 0.68x | 1.39x | 0.29x | 0.31x | 0.65x | 0.64x | 0.82x | 0.81x | 0.86x | 0.80x | 0.84x | 0.99x | 0.90x | 0.84x | 0.70x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying NBTX stock.
Nanobiotix S.A. (NBTX) generated $-33.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Nanobiotix S.A. (NBTX) reported negative free cash flow of $34.0M in 2025, indicating capital requirements exceeded cash from operations.
Nanobiotix S.A. (NBTX) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Milestone-dependent cash runway
Losses Consistently Exceed Operating Cash Burn
According to reported quarterly figures, NBTX posted a 2026Q2 net loss of $34.7M against operating cash flow of negative $22.3M, an OCF-to-net-income ratio of 0.64 that signals meaningful non-cash or non-operating charges sitting beneath the reported loss.
The gap between net loss and operating cash outflow suggests that a meaningful portion of the reported deficit is non-cash, which may include amortization or accounting charges tied to collaboration accounting. Because the ratio is positive in most quarters but reverses sign in 2023Q4 when operating cash flow turned briefly positive, the conversion pattern appears driven by the timing of partner receipts rather than a durable operating improvement. Investors should monitor whether the reconciliation between net loss and operating cash flow narrows as milestone recognition normalizes.
Free Cash Flow Remains Persistently Negative
Based on reported figures, NBTX's free cash flow was negative $23.0M in 2026Q2 on a -4.1% margin, and across the ten-quarter window only one quarter, 2023Q4, produced positive free cash flow of $4.8M.
The trajectory points to a company whose free cash flow is structurally negative, with the single positive quarter appearing to reflect a lumpy partner payment rather than a repeatable cash generation capability. Free cash flow margins in several periods, such as 2024Q4 at 85.4%, are distorted by negative revenue denominators and should not be read as improvement. The persistent burn suggests the business depends on external funding and partner receipts to sustain clinical operations, which warrants further investigation into the timing of future milestone inflows.
Minimal Capital Intensity Despite Clinical Scale
As reported in financial statements, NBTX's capital expenditure ran between near-zero and $635K per quarter in 2026Q2, equal to roughly 11.4% of revenue, indicating a capital-light asset base for a company of its clinical footprint.
The low absolute capex level is consistent with an outsourced development model in which manufacturing and trial execution are contracted rather than owned. Depreciation and amortization of roughly $0.8M per quarter sitting well above recent capex levels suggests the asset base is being run down rather than replaced, which may indicate limited investment in future production capacity. Investors should monitor whether capex rises as the company moves toward commercial manufacturing, since the current spending pattern does not yet reveal the infrastructure required for a product launch.
Working Capital Swings Mask Underlying Burn
Based on reported figures, NBTX's working capital change moved from a $4.4M outflow in 2026Q2 to a $2.6M inflow in 2024Q4, a swing large enough to materially shift reported operating cash flow between quarters.
The alternating direction of working capital movements points to timing differences in receivables, deferred revenue, and accrued clinical costs rather than a steady operating trend. Because the sign flips frequently, quarter-to-quarter operating cash flow figures are not a reliable read on the underlying burn rate. Analysts should focus on trailing multi-quarter cumulative operating cash flow when assessing the company's true consumption.
Cumulative Losses Outpace Cash Generation
Across the ten reported quarters, NBTX accumulated net losses that substantially exceed its cumulative operating cash flow, with most quarters showing negative operating cash flow and only a single quarter of positive free cash flow.
The cumulative divergence between reported losses and cash reality suggests a business whose accounting results are shaped by non-cash items and partner revenue recognition, while its cash position reflects continuous consumption. This pattern may indicate the balance sheet cash cushion is being drawn down steadily, with runway dependent on future partner payments and financing. The divergence warrants monitoring against any disclosed cash balance trajectory.
Positive Quarters May Flatter the Burn Picture
Based on reported figures, the single positive free cash flow quarter in 2023Q4 and the 2025Q2 operating cash flow ratio of 3.23 could be misread as an inflection, while the broader ten-quarter pattern points to continued consumption.
Isolated positive quarters driven by partner receipts or working capital timing may create an impression of improving cash generation that the cumulative data does not support. Ratios such as OCF-to-net-income become unstable when net income is near zero or negative, so headline conversion figures should be interpreted cautiously. Investors should treat any future positive cash quarter as confirmation only if it recurs without a milestone payment behind it.